Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

BioPharm International: Modernizing Intranasal Live Attenuated Vaccines

Biotech 2050 Podcast: An End Game Vaccine for COVID-19

Meissa Vaccines Appoints Dr. Michael Watson to Board of Directors

BioSpace: Meissa’s Intranasal COVID-19 Vaccine Uses Codon Deoptimization for Stronger Responses

Meissa Announces IND Clearance for Phase 1 Study of COVID-19 Intranasal Live Attenuated Vaccine

Meissa Announces 1st Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV

Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Candidates

San Francisco Business Times: Covid Vaccine Player Hopes to Start Clinical Trial Early Next Year

BioSpace: Another COVID-19 Vaccine Joins the Race – This Time, it’s a Live, Weakened Virus

Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV

Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine

FierceBiotech: Meissa Raises $30M to Take RSV Vaccine into the Clinic

Meissa Vaccines Closes $30 Million Financing to Advance RSV Vaccine into Clinical Trials

Xconomy: Meissa Scores $30M to Test Vaccine for Dangerous Respiratory Virus

Endpoints: Meissa Obtains $30M Series A to Test Synthetic Biology Approach to 'Elusive' RSV Vaccines

Meissa Vaccines Closes $3.4 Million Financing to Advance RSV Vaccine to Clinic

Meissa Vaccines Announces Seed Round Investment from FundRx

Meissa Vaccines Awarded NIH SBIR Grant to Advance IND Preparations for RSV Vaccine Candidate

Meissa Vaccines Receives FDA Clearance of IND Application, Phase 1 Clinical Trial of MV-012-968

Meissa Awarded NIH SBIR Grant to Support Development of Multivalent Human Rhinovirus Vaccine Candida